Company profile

CatalYm GmbH

Privately held: no public share price (Private German clinical-stage oncology biotech; $150M Series D closed 2024, no listing found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.catalym.com/catalym-announces-new-financing-of-150m-to-support-broad-phase-2b-development-program-for-visugromab/]) · Germany

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Visugromab
Phase 2
GDF-15Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.